GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

Older adults with advanced kidney disease are often motivated to receive a transplant but may face emotional and psychosocial ...

Body weight cycling, also known as “yo-yo dieting,” is associated with a 25%-36% increased risk for diabetic kidney disease ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

This article reviews the current use of rituximab in renal disease and transplantation, and includes discussion of the drug's potential role in novel therapeutic protocols. Rituximab, a monoclonal ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.